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OReply to: ‘‘Controversy on the role of FoxP3+ regulatory T cells
in ﬁbrogenesis in chronic hepatitis C virus infections’’Diversity of Foxp3+CD4+ T cells and regulation of ﬁbrosis in
hepatitis C – At the tip of the iceberg?
To the Editor:
We are grateful that Claassen et al. draw attention to several
issues in our manuscript on ‘‘Intrahepatic IL-8 producing
Foxp3+CD4+ regulatory T cells and ﬁbrogenesis in chronic
hepatitis C’’ [1] which had not been discussed in depth and thus
might lead to misleading conclusions.
We agree, that IL-8+Foxp3+CD4+ T cells comprise only a small
population of intrahepatic immune cells and that other types of
intrahepatic cells also produce IL-8. However, in line with the
report by Zimmermann et al. [2], macrophages were the only
other cells in hepatitis C, which in addition to CD4+ T cells pro-
duced sufﬁcient IL-8 as to enable in situ detection by immunoﬂu-
orescence. Unlike IL-8+CD4+ T cells, which were located
preferentially at the boundaries of ﬁbrotic areas, macrophages
formed cell clusters at regions of necrosis and inﬂammation
(see Fig. 1). Furthermore, IL-8+CD4+ T cells can be triggered by
HCV antigens [3] and thus are probably activated continuously
by antigen in chronic hepatitis C. Taken together these ﬁndings
suggest a regulatory role of IL-8+CD4+ T cells in HCV-infected liv-
ers. In support of this hypothesis we directly demonstrated
induction of ﬁbrogenesis in primary human hepatic stellate cells
by in vitro co-culture experiments. As reported previously the
same type of IL-8 producing CD4+ regulatory T cells also exerts
other functions, e.g., our regulatory T cell clones inhibit activity
of CD4+ effector T cells by releasing the cytokines IL-10 and IL-
35 [3].
Concerning interferon-c the comment of Claassen et al.
illustrates that data frommicroarray analysis must be interpreted
with caution. As can be seen in the supplementary ﬁle to our
previously published data [3], the regulatory T cell clones studied
by microarray analysis (T1_7, H7_3, H7_16) only produced
negligible amounts of interferon-c even upon stimulation with
mitogen (<5 pg/ml), whereas bona ﬁde TH1 cells produced
800–6000 pg/ml under the same conditions. Of note, the regula-
tory T cell clones even suppressed interferon-c production of TH1
reporter cells in co-culture experiments (see Fig. 2). This consti-
tutes further experimental evidence suggesting a dual role of
Foxp3+CD4+ regulatory T cells in both regulation of ﬁbrosis and
inhibition of inﬂammatory activity. To guard against false inter-
pretation of our microarray data, we have conﬁrmed at the
protein level that regulatory T cell clones as well as freshly iso-
lated Foxp3+CD4+ T cells produce IL-8 in chronic hepatitis C.
These ﬁndings indicate that IL-8 production of regulatory T cells32 Journal of Hepatology 2014 vol. 60 j 229–236
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hepatitis C, may have ‘‘diluted’’ the analysis of regulatory T cells
with respect to total leucocytes resulting in an apparent decline
in advanced ﬁbrosis.
We did not study IL-8+ regulatory T cells under treatment
with interferon and ribavirin combination therapy and thus can-
not comment on persistence of these cells after therapeutic clear-
ance of HCV infection. However, we want to draw attention to a
previous brief report by Bahra et al. who studied evolution of
ﬁbrosis progression in hepatitis C when patients had achieved
sustained viral clearance after therapy [7]. In serial biopsies taken
before 1, 3, and 5 years after sustained response they observed a
delayed reduction of ﬁbrosis scores over the ﬁrst 3 years. This
ﬁnding might be well compatible with persisting of proﬁbrotic
regulatory cells after viral clearance as reported by Claassen
et al. [8].
We hope that the additional data provided in our response
helps to clarify the invaluable comments of Claassen and Boon-
stra, which highlight the complexity of regulatory T cell involve-
ment in the pathogenesis of chronic hepatitis C. Part of regulatory
T cell heterogeneity probably results from the fact that a uniform
marker to identify this population has not yet been established,
making it necessary to identify regulatory T cells by a panel of
multiple features. Thus, it is difﬁcult to ascertain if regulatory T
cells in hepatitis C reported by different authors actually refer
to the same T cell population. By demonstrating that Foxp3+CD4+
regulatory T cells in hepatitis C can exert dual functions – both
inhibition of T effector cells and activation of hepatic stellate cells
– our manuscript illustrates that functional heterogeneity of
regulatory T cells exists and must be considered in future studies.
Multiple issues remain to be resolved. Thus, we do not know if
dual functionality is acquired sequentially at different stages of
hepatitis C or if exists in HCV-associated regulatory T cells right
from the beginning. To be frank we fear that current knowledge
on the heterogeneity of regulatory T cells may only reﬂect the
tip of the iceberg.
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Fig. 1. Cluster of IL-8 producing macrophages at regions of necrosis and
inﬂammation. Location of IL-8-positive (green) macrophages in a liver cryostat
section from chronic hepatitis C (Metavir Score F4). Red ﬂuorescence marks CD4+





















Fig. 2. Inhibition of IFN-c production in TH1 clones by Treg clones. Inhibition
of IFN-c production in the TH1 reporter clone (Trep; cloneT5_4) by co-culture
with the autologous regulatory T-cell clone (Tr; clone T1_7). Results give means
and standard error of the number of spot forming cells (SFC) in an ELISpot assay.
JOURNAL OF HEPATOLOGYmay reﬂect distinct T cell differentiation associated with chronic
hepatitis C (and possibly also some other infections). Indeed sev-
eral in vitro studies have demonstrated that HCV proteins, HCV
transfection, and experimental infection are associated with acti-
vation of the IL-8 promoter and IL-8 production (see references
30 to 44 in our publication).
Concerning the putative relationship between regulatory T
cells and stages of ﬁbrosis, a closer look reveals that our data
are rather similar to those reported previously in the Journal of
Hepatology by Wards et al. and Sturm et al. [4,5]: both authors
stated that the ‘‘relative proportion of Foxp3+ cells remains sim-
ilar in both mild and severe ﬁbrosis’’. This statement holds also
true in our study, where the relationship between numbers of
Foxp3+CD4+ regulatory T cells and ﬁbrosis indicated only a small
non-signiﬁcant trend when IL-8 secretion was not taken into
account separately (rS = 0.274, p = 0.185). Thus, it is not the num-
ber of regulatory T cells but their fraction with differentiation
towards IL-8 production that increases with progressive ﬁbrosis.
Moreover, the apparent discrepancy of these previous reports
(including our own) to the data of Claassen et al. [6], probably
reﬂects a difference in the reference frame for reporting numbers
of regulatory T cells: frequencies of regulatory T cells were given
with respect to numbers of total liver leucocytes by Claassen
et al., whereas in our study numbers of IL-8+Foxp3+CD4+ regula-
tory T cells were reported as fraction of CD4+ T cells. Thus, it
might be quite possible that inﬂammatory cells other than T cells,
which accumulate in liver tissue during progression of chronicJournal of Hepatology 2014 vol. 60 j 229–236 233
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From the CUPIC study: Great times are not coming (?)
To the Editor:
We read with interest the article by Hézode et al., in which they
describe the week 16 interim results from the CUPIC study, a
large French multicenter prospective cohort study [1]. Given
the strict inclusion criteria of protease inhibitors (PI) phase III tri-
als, the cirrhotic group was underrepresented and composed of
highly selected patients in these studies [2–5]. Therefore, efﬁcacy
and safety concerns about ﬁrst-generation PI-based therapy in
‘‘real-life’’ cirrhotic patients were raised. The CUPIC investigators
found that albumin levels <35 g/L and platelet count 6100,000/
mm3 were independent predictors of death and severe complica-
tions, and the risk of these events in patients with both predictors
was worryingly high (44.1%). The ﬁndings from the CUPIC study,
important as they are, need to be qualiﬁed given two important
caveats that we would like to discuss.
First, as the authors mentioned in the methods section, the
safety interim analysis was not pre-speciﬁed in the original pro-
tocol and the sample size was not estimated for this purpose.
As a result, the study was probably underpowered to investigate
factors associated with such a low incidence event (death or
severe complications). This issue is even more relevant when
we analyze the number of variables included in the multivariate
analysis presented in Table 3. It is generally recommended that
a minimum of 10 events per variable should be used in logistic
regression models, since increasing bias and variability, unreli-
able conﬁdence interval coverage, and problems with model con-
vergence emerge as the events per variable ratio declines below
10 and especially below ﬁve [6,7]. In the article by Hézode and
colleagues, the multivariate analysis included 12 variables found
to be associated with death or severe complications in univariate
analysis, whereas only 32 events occurred (2.7 events per variable
included). The adequate interpretation of the model is further
hampered by the probable signiﬁcant multicollinearity between
several independent variables included, like bilirubin, albumin,
Child-Pugh score and MELD score.
Based on the ﬁgures shown on the article’s Table 4, we have
calculated the accuracy parameters for albumin levels <35 g/L
and platelet count 6100,000/mm3, either alone or in combina-
tion, for the prediction of death or severe complications (Table 1).
Albumin exhibited higher speciﬁcity as compared to platelet
count (89% vs. 79%), with comparable sensitivity (57% vs. 60%).
Moreover, the positive likelihood ratio (LR+) was much higher
for low albumin levels than low platelet count (5.02 vs. 2.82).
When both parameters were used in combination, there was a
modest gain in speciﬁcity (95%) and a signiﬁcant increase in
LR+ (10.50). Given that the LR+ tells us how much to increase
the probability of event if the test is positive, these results
indicate that a serum albumin level <35 g/L can indeed be
regarded as a good predictor of death and severe complications
in cirrhotic patients treated with ﬁrst-generation PI-based
regimens, particularly when associated with a platelet count
6100,000/mm3. Interestingly, the negative predictive value was
high (>95%) for all parameters, which can prove to be a reassuring
ﬁnding and a valuable tool if conﬁrmed in other cohorts.
In conclusion, although we acknowledge the unquestionable
importance of the CUPIC study, we believe that its results do
not support the author’s deﬁnitive conclusion that treatment-
experienced cirrhotic patients with platelet count and albumin
levels below the mentioned cutoffs should not be treated with
telaprevir or boceprevir. Conceivably, additional studies will be
able to conﬁrm CUPIC’s ﬁndings, or will even propose alternative
strategies for high risk patients, like antibiotic prophylaxis or low
accelerating dose regimen for interferon. Until then, we believe
that triple therapy should not be denied to patients who do not
meet the proposed albumin/platelet criteria, but rather they
should be treated in specialized centers with liver transplant
programs, by experienced hepatologists. The current approved
PI-based regimen will probably be the standard-of-care for HCV
patients for many years in several countries and, even though
IFN-free regimens are coming, it may be a very distant reality
for many cirrhotic patients at risk for decompensation in the near
future.
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